Thyroid eye disease
Thyroid eye disease and targeted treatments such as teprotumumab.
Key point
IGF-1R inhibitors outperformed placebo across multiple thyroid eye disease efficacy outcomes, particularly in active disease, but increased adverse-event risk warrants vigilant monitoring.
From: Efficacy and Safety of IGF-1 Receptor Inhibitors for Thyroid Eye Disease: Systematic Review and Meta-analysis of Randomized Controlled Trials (Drugs, 2026 Sep 24) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 14, 15, 32, 22, 39.
New guidelines and consensus this year
- WSOPRAS and ITEDS Consensus Statement on the Assessment and Management of Thyroid Eye DiseaseOphthalmic Plast Reconstr Surg2026 Sep 2
- Comparison of the 2021 EUGOGO guidelines and the 2022 ATA/ETA consensus statement for the management of Graves' orbitopathyEur Thyroid J2025 Dec 1
All papers from the last 12 months
503 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Roles of T cell subpopulations in thyroid eye diseaseAutoimmunity2026 Dec 31PMID 41589802Review
- Upper eyelid retraction: meta-analysis & systematic review of surgical outcomesJPRAS Open2026 NovPMID 42834887Review
- Non-surgical management of thyroid eye disease: a pilot survey of oculoplastic surgeonsInt Ophthalmol2026 Oct 16PMID 42886427
- Anatomical-Persistent Synergy Mamba for Joint Pre-to-Postoperative CT Synthesis and Multi-structure Segmentation in Orbital Decompression SurgeryIEEE J Biomed Health Inform2026 Oct 15PMID 42879269
- Veligrotug: First ApprovalDrugs2026 Oct 13PMID 42864578
- Emerging Therapeutic Strategies for Graves' Disease: Current Advances and Future PerspectivesCurr Pharm Des2026 Oct 9PMID 42872677
- Microsurgical two-wall orbital decompression for treatment of visual impairment in patients with thyroid-associated ophthalmopathyEur J Ophthalmol2026 Oct 9PMID 42852894
- Ocular Hypertension and Glaucoma in Graves' Orbitopathy: A Single-Center Retrospective Cross-Sectional StudyJ Clin Med2026 Oct 8PMID 42882200
- Tear interleukin-6 and clinical activity in thyroid eye diseaseBiomol Biomed2026 Oct 8PMID 42848915
- Smartphone-Based Deep Learning Exophthalmometry in Thyroid Eye Disease: A Multicenter, Multiethnic Validation StudyThyroid2026 Oct 7PMID 42844709
More endocrinology trends
All specialties →Automated insulin delivery
Hybrid closed-loop systems that adjust insulin automatically.
Primary aldosteronism
Screening, diagnosis and treatment of primary aldosteronism.
Key point: Universal screening for primary aldosteronism in all patients with hypertension with an aldosterone-to-renin ratio test is now recommended.
Menopausal hormone therapy
Hormone therapy for menopausal symptoms, benefits and risks.
CGM in type 2 diabetes
Continuous glucose monitoring for people with type 2 diabetes.
Key point: CGM is strongly recommended for people with type 2 diabetes treated with insulin and those not treated with insulin, particularly when HbA1c is ≥7%.
Anabolic osteoporosis treatment
Romosozumab, abaloparatide and teriparatide for osteoporosis.
Key point: Abaloparatide has efficacy and safety similar to teriparatide and represents a new option for patients with severe osteoporosis and very high fracture risk.
Cell therapy for type 1 diabetes
Islet transplantation and stem cell-derived beta cells.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
"thyroid eye disease"[tiab] OR teprotumumab[tiab] OR "Graves' orbitopathy"[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.